Testing for pancreatic cancer typically begins with a specialized CT scan and may involve additional imaging, blood tests, and a biopsy depending on what the initial scan reveals. There is no single, simple screening test for pancreatic cancer the way a mammogram screens for breast cancer, which is one reason the disease is often caught late. But the diagnostic tools available today are highly accurate when used in the right sequence.
Pancreas Protocol CT: The First-Line Test
The standard starting point is a pancreas protocol CT scan, a specialized version of a regular CT that captures images at precise moments after contrast dye is injected. About 93% of medical centers use this scan as their go-to when pancreatic cancer is suspected. It works by taking two sets of images: one roughly 35 to 40 seconds after the dye injection (when the pancreas itself lights up most clearly) and another at about 70 seconds (when the veins surrounding the pancreas are best visualized). This two-phase approach lets doctors see both the tumor and whether it’s growing into nearby blood vessels.
The scan is 90% sensitive and 99% specific for detecting solid pancreatic tumors. In practical terms, that means it catches 9 out of 10 cancers and almost never flags something as cancer when it isn’t. You’ll typically drink about 500 to 1,000 mL of water in the 20 to 30 minutes before the scan to fill and expand your stomach and the first part of your small intestine, giving the radiologist a clearer view.
A regular CT scan done without this specific timing and technique can miss smaller tumors or fail to show whether the cancer has wrapped around critical blood vessels. If you’ve only had a standard abdominal CT, your doctor may order a dedicated pancreas protocol scan for a more detailed look.
Endoscopic Ultrasound and Biopsy
When imaging finds a suspicious mass, the next step is usually an endoscopic ultrasound, or EUS. A thin, flexible tube with a small ultrasound probe on its tip is passed through your mouth, down through your stomach, and into the upper part of your small intestine, which sits right next to the pancreas. From there, the ultrasound can produce extremely close-up images of the pancreas and surrounding tissue.
The real value of EUS is that it allows a biopsy at the same time. A needle is passed through the scope and into the mass to collect a tissue sample. Modern biopsy needles are wide enough to retrieve small cores of tissue rather than just individual cells, which gives pathologists more to work with. That tissue can then be examined under a microscope and tested for specific genetic markers that help guide treatment decisions.
Preparation is straightforward. You’ll need to fast for at least six hours beforehand so your stomach is empty. The procedure is done under sedation, so you won’t be awake for it. Most people go home the same day, though you’ll need someone to drive you because of the sedation. Mild throat soreness or bloating afterward is common and short-lived.
The CA 19-9 Blood Test
CA 19-9 is a protein that pancreatic cancer cells often release into the bloodstream. A normal level is below 37 units per milliliter. At that cutoff, the test catches about 81% of pancreatic cancers and correctly rules it out about 90% of the time. Those numbers aren’t strong enough to diagnose pancreatic cancer on their own, which is why CA 19-9 is never used as a standalone screening tool.
Where CA 19-9 becomes more useful is in tracking the disease over time. A rising level after treatment can signal that the cancer is coming back. Very high levels (above 1,000 U/mL) are also strongly associated with more advanced disease. At that threshold, the test is 99.8% specific, meaning an extremely high reading is almost certainly not a false alarm. But because it misses more than half of cancers at that cutoff, a normal or mildly elevated CA 19-9 doesn’t rule anything out.
It’s also worth knowing that some people simply cannot produce CA 19-9 due to their blood type (roughly 5 to 10% of the population), so their levels will always read as low regardless of whether cancer is present.
MRI and Duct Imaging
A specialized MRI called MRCP (magnetic resonance cholangiopancreatography) can visualize the pancreatic and bile ducts without any needles, dye injections, or sedation. It’s a noninvasive alternative to an older technique called ERCP, which threads a scope into the ducts themselves. MRCP has a diagnostic accuracy of about 92% and successfully produces usable images in roughly 98% of patients.
MRCP is particularly helpful when doctors suspect a tumor is blocking one of these ducts, which is a common cause of jaundice in pancreatic cancer. ERCP is still used, but primarily when doctors need to place a stent to relieve a blocked duct rather than purely for diagnosis.
Staging Laparoscopy
Even with excellent imaging, somewhere between 11% and 48% of patients who appear to have surgically removable tumors turn out to have cancer that has already spread to places too small for a CT scan to detect. To avoid putting patients through a major operation unnecessarily, surgeons sometimes perform a staging laparoscopy first: a minimally invasive procedure where a small camera is inserted through a tiny incision in the abdomen to look directly at the liver surface and the lining of the abdominal cavity for tiny metastases.
This step is most often considered for tumors larger than 3 centimeters, tumors located in the body or tail of the pancreas (rather than the head), and patients whose CA 19-9 levels are above 150 U/mL. All of these factors are associated with a higher chance that cancer has quietly spread beyond what imaging can see.
Genetic Testing for Inherited Risk
Current guidelines recommend that anyone diagnosed with pancreatic cancer undergo genetic testing to look for inherited gene mutations. The most commonly tested genes include BRCA1, BRCA2, PALB2, ATM, and those associated with Lynch syndrome. Finding one of these mutations matters because it can open the door to targeted therapies and also alerts family members that they may carry an elevated risk.
For people who haven’t been diagnosed but have a strong family history, screening is recommended in specific situations. You’re generally considered a candidate for regular surveillance if you have two or more genetically related family members (at least one a first-degree relative) who’ve had pancreatic cancer. People who carry certain gene mutations, including BRCA1, BRCA2, PALB2, ATM, and CDKN2A, are also advised to screen even with just one affected relative in some cases. Those with Peutz-Jeghers syndrome or hereditary pancreatitis qualify for screening regardless of family history due to their substantially elevated risk.
Screening for high-risk individuals typically involves annual EUS or MRI rather than CT, since these tests avoid repeated radiation exposure over what may be many years of surveillance. Screening usually begins around age 50 or 10 years younger than the earliest case in the family, whichever comes first.
What No Test Can Do Yet
There is currently no widely available blood test that reliably detects pancreatic cancer at its earliest, most treatable stage in the general population. A blood-based test analyzing tiny fragments of RNA released by tumors has shown accuracy as high as 93% in early research, and when combined with CA 19-9, that figure rose to 97% for early-stage disease in one U.S. study group. But these results have not yet been validated through the rigorous, large-scale studies needed before such a test could be offered routinely. For now, imaging and biopsy remain the backbone of diagnosis, and the best path to early detection for those at elevated risk is enrollment in a formal screening program.